Dr. Reddy’s to Release Q3 FY19 Results on February 1, 2019
HYDERABAD, India--(BUSINESS WIRE)--Jan 11, 2019--Dr. Reddy’s Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the quarter ended December 31, 2018 on Friday, February 1, 2019 after the Board Meeting.
Summary of Events
Following the release, the management of the Company will host an earnings call to discuss the Company’s financial performance. (Dial In and other details given below)
The play back will be available after the earnings call, through February 7 th, 2019. For play back dial in phone No: 022 7194 5757 / 022 6663 5757, and Playback Code is 37176.
No password/pin number is necessary to dial in to any of the above numbers. The operator will provide instructions on asking questions before and during the call.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy’s operates in markets across the globe. Our Major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.
The company assumes no obligation to update any information contained herein.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190111005109/en/
CONTACT: INVESTOR RELATIONS
KEYWORD: UNITED STATES ASIA PACIFIC NORTH AMERICA NEW YORK INDIA
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Dr. Reddy’s Laboratories Ltd.
Copyright Business Wire 2019.
PUB: 01/11/2019 04:57 AM/DISC: 01/11/2019 04:57 AM